Online Only Articles

Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy

Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo
Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka;Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa
Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo;Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo
Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo
Vol. 104 No. 11 (2019): November, 2019 https://doi.org/10.3324/haematol.2018.208876